Biosimilar Use, Cost Trends In Medicare Part B Will Be Examined By HHS Inspector General
If study finds biosimilar uptake in the Part B program is lagging, it may inform policy changes to encourage gains. On the other hand, the latest biosimilars trend reports from Cardinal Health and Amgen show follow-ons are controlling share in some markets for physician-administered drugs and savings are adding up.
You may also be interested in...
Senate Finance Committee staffer explains Republicans are inclined to support more moderate approaches in the near term as the 'bigger ideas' for promoting biosimilars evolve.
But even with the legislative and regulatory changes proposed by the Biosimilars Forum, market share would still not reach levels seen in Europe, an analysis by Avalere finds.
US legislation attempts to address manufacturer, pharmacy benefit manager impact on patient costs in addition to health plan benefit designs. Critics suggest it’s too easy on manufacturers but that may help its chances with Republicans.